Nurix therapeutics receives u.s. fda fast track designation for nx-5948 for the treatment of relapsed or refractory cll and sll

Fast track designation follows positive phase 1 data presented at the american society of hematology that supports strategy to broadly develop nx-5948 in cll and other non-hodgkin lymphoma indications fast track designation follows positive phase 1 data presented at the american society of hematology that supports strategy to broadly develop nx-5948 in cll and other non-hodgkin lymphoma indications
NRIX Ratings Summary
NRIX Quant Ranking